Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Purchased by Wellington Management Group LLP

Wellington Management Group LLP lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 8.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,482,105 shares of the company's stock after purchasing an additional 280,240 shares during the period. Wellington Management Group LLP owned about 4.92% of Nurix Therapeutics worth $78,243,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Driehaus Capital Management LLC acquired a new position in Nurix Therapeutics in the 2nd quarter worth $26,778,000. Candriam S.C.A. increased its position in shares of Nurix Therapeutics by 30.5% during the second quarter. Candriam S.C.A. now owns 1,164,246 shares of the company's stock worth $24,297,000 after acquiring an additional 272,136 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in shares of Nurix Therapeutics by 12.6% in the second quarter. Affinity Asset Advisors LLC now owns 912,000 shares of the company's stock worth $19,033,000 after acquiring an additional 101,747 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Nurix Therapeutics by 60.2% in the second quarter. Millennium Management LLC now owns 599,623 shares of the company's stock worth $12,514,000 after acquiring an additional 225,374 shares in the last quarter. Finally, FMR LLC boosted its holdings in Nurix Therapeutics by 675.9% in the third quarter. FMR LLC now owns 586,902 shares of the company's stock valued at $13,188,000 after purchasing an additional 511,256 shares during the last quarter.

Insiders Place Their Bets

In other news, CFO Houte Hans Van sold 3,546 shares of the firm's stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the transaction, the chief financial officer now directly owns 33,724 shares of the company's stock, valued at approximately $818,818.72. This trade represents a 9.51 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christine Ring sold 3,290 shares of the company's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $25.00, for a total transaction of $82,250.00. Following the completion of the sale, the insider now directly owns 24,592 shares of the company's stock, valued at $614,800. The trade was a 11.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,401 shares of company stock worth $437,453. Insiders own 7.20% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the company. Stephens restated an "overweight" rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. Royal Bank of Canada dropped their price target on shares of Nurix Therapeutics from $27.00 to $26.00 and set an "outperform" rating for the company in a research note on Monday, October 14th. BMO Capital Markets initiated coverage on shares of Nurix Therapeutics in a research note on Friday, December 6th. They set an "outperform" rating and a $35.00 price objective on the stock. Jefferies Financial Group began coverage on shares of Nurix Therapeutics in a report on Friday, October 11th. They set a "buy" rating and a $41.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $29.00 target price on shares of Nurix Therapeutics in a research note on Tuesday. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $30.35.

Nurix Therapeutics Trading Down 3.4 %

NRIX traded down $0.75 during trading on Wednesday, reaching $21.31. 817,609 shares of the company were exchanged, compared to its average volume of 904,775. Nurix Therapeutics, Inc. has a 52 week low of $7.65 and a 52 week high of $29.56. The firm has a 50 day moving average of $23.72 and a 200 day moving average of $22.10. The stock has a market cap of $1.51 billion, a P/E ratio of -7.58 and a beta of 2.11.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative net margin of 313.65% and a negative return on equity of 63.39%. The business had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. As a group, analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.